Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624364 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL3835254 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31299005 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL3199882 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL26654416 | 0.99 | CASP3 (0.58) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL26654411 | 0.99 | CASP3 (0.58) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL5846051 | 0.93 | CASP3 (0.55) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL3230119 | 0.92 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL7198189 | 0.92 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL3725037 | 0.92 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368680-A1 | METHOD FOR PRODUCING SALT OF AMINO ACID OR SALT OF PEPTIDE COMPOUND OR SOLVATE OF EITHER ONE OF SAID SALTS COMPRISING LITHIUM SALT PRECIPITATION STEP | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-4520748-A1 | METHOD FOR PRODUCING SALT OF AMINO ACID OR SALT OF PEPTIDE COMPOUND OR SOLVATE OF EITHER ONE OF SAID SALTS COMPRISING LITHIUM SALT PRECIPITATION STEP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023219152-A1 | METHOD FOR PRODUCING SALT OF AMINO ACID OR SALT OF PEPTIDE COMPOUND OR SOLVATE OF EITHER ONE OF SAID SALTS COMPRISING LITHIUM SALT PRECIPITATION STEP | 中外製薬株式会社 | 2023-11-16 | — | — | WO | disclosed |
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-9682123-B2 | Methods of treating metabolic disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150190466-A1 | METHODS OF TREATING METABOLIC DISEASE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-09 | — | — | US | disclosed |
| US-20130160150-A1 | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE LISCH-LIKE PROTEIN OR C1ORF32 PROTEIN ACTIVITY AND METHODS OF USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-06-20 | — | — | US | disclosed |
| US-8460880-B2 | Compositions, splice variants and methods relating to ovarian specific genes and proteins | DIADEXUS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-7678889-B2 | Compositions and methods relating to ovarian specific genes and proteins | DIADEXUS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-1333755-A | Benzimidazole compounds as vitronectin receptor antagonists | SCHERING CORP (US) | 2002-01-30 | — | — | CN | disclosed |
| WO-2001092524-A2 | MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE | AEOMICA, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-1135374-A1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1115724-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | Shire Biochem Inc. (CA) | 2001-07-18 | — | — | EP | disclosed |
| US-6204282-B1 | TREATING CANCER, RETINOPATHY, ATHEROSCLEROSIS, VASCULAR RESTENOSIS, OR OSTEOPOROSIS. | SCHERING CORPORATION | 2001-03-20 | — | — | US | disclosed |
| EP-1021424-A1 | THIADIAZOLE AMIDE MMP INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000032578-A1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000017197-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | BIOCHEM PHARMA INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| US-5830869-A | METALLOPROTEASE INHIBITOR | PHARMACIA & UPJOHN COMPANY | 1998-11-03 | — | — | US | disclosed |
| WO-1997048688-A1 | THIADIAZOLE AMIDE MMP INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368680-A1 | METHOD FOR PRODUCING SALT OF AMINO ACID OR SALT OF PEPTIDE COMPOUND OR SOLVATE OF EITHER ONE OF SAID SALTS COMPRISING LITHIUM SALT PRECIPITATION STEP | NPPA, DNPEP, NPEPPS | CASP3 2635/4885KMT2A 3331/4885MDM4 2388/4885 |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | UGT2B7, CYP3A7, STS | CASP3 104/4885KMT2A 2404/4885MDM4 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.